ING Groep NV Has $57.13 Million Stake in Zoetis Inc. $ZTS

ING Groep NV raised its position in Zoetis Inc. (NYSE:ZTS) by 1,351.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 454,053 shares of the company’s stock after purchasing an additional 422,760 shares during the quarter. ING Groep NV’s holdings in Zoetis were worth $57,129,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. JPMorgan Chase & Co. decreased their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, UBS Group decreased their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus target price of $133.92.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis published the company’s 2025 Sustainability Report, highlighting progress in animal health and its next phase of sustainability goals. Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
• Neutral Sentiment: The stock saw unusual call-option buying, suggesting some traders are positioning for a rebound despite the recent selloff. Zoetis (ZTS) rises as investors refocus on outlook and precision-animal-health expansion
• Neutral Sentiment: Zoetis’ valuation is being reassessed after its guidance cut and ongoing concerns about companion-animal demand and legal issues. A Look At Zoetis (ZTS) Valuation After Guidance Cut Legal Actions And Companion Animal Headwinds
• Negative Sentiment: Jim Cramer said he prefers Elanco over Zoetis, adding to negative investor sentiment around ZTS. Jim Cramer Recommends Elanco Over Zoetis
• Negative Sentiment: Multiple law firms announced or promoted class-action lawsuits against Zoetis, with allegations tied to alleged misleading statements, FDA safety warnings, and market-share erosion. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The company is also facing investor-notice deadlines and additional securities-fraud claims, keeping legal overhang front and center for shareholders. INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Zoetis Stock Performance

ZTS opened at $79.49 on Friday. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $171.52. The firm has a market capitalization of $33.33 billion, a PE ratio of 13.18, a PEG ratio of 1.24 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The business’s 50-day simple moving average is $100.52 and its 200 day simple moving average is $115.54.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.